Publicaciones

1. Therapeutic Effectiveness of Interferon-a2b Against COVID-19: The Cuban Experience
2. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
3. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
4. COVID-19 Lethality in Sub-Saharan Africa and Helminth Immune Modulation
5. Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1
6. CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients
7. Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients
8. La industria biofarmacéutica cubana en el combate contra la pandemia de COVID-19
9. Publicaciones

Covid-19: Resultado de Ensayos Clinicos 

1. – REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. NCT04425629.
2. – SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. NCT04427501.
3. – Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. NCT04436276.
4. – Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. NCT04338360.
5. – Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NCT04470427.